logo
Products
Services
Resources
Selection Guides
About
iFluor® 555 Anti-human CD109 Antibody
W7C5
The W7C5 monoclonal antibody binds with human CD109, a 162 kD transmembrane protein typically expressed on the surface of T cells and T cell lines. CD109 acts in essential cellular pathways, for instance, the negative regulation of transforming growth factor beta receptor signaling pathway. Additionally, in some organisms, it is a suppressor of transforming growth factor beta receptor signaling pathway, is a repressor of wound healing and is a repressor of keratinocyte proliferation. From a research standpoint, it is of biological interest due to its association with critical macromolecules/ligands. CD109 is a relatively rare antibody target, with fewer than 600 publications in the last decade. Even still, CD109 is vital to immunology research, frequently serving as a phenotypic marker for differentiating cell types in flow cytometric applications. This antibody was purified through affinity chromatography and conjugated to iFluor® 555 (ex/em = 557/570 nm). It is compatible with the 561 nm laser and 577/35 nm bandpass filter (for example, as in the Luminex Amnis ImageStream).
product image
product image
CatalogSize
Price
Quantity
11090090100 tests
Price
11090091500 tests
Price
 
Antibody properties

Other namesCPAMD7, Gov platelet alloantigen
CloneW7C5
HostMouse
IsotypeIgG1
ReactivityHuman
ApplicationFlow Cytometry (FACS), Fluorescence Imaging
Spectral properties

Correction factor (260 nm)0.23
Correction factor (280 nm)0.14
Extinction coefficient (cm -1 M -1)
100000
1
Excitation (nm)557
Emission (nm)570
Quantum yield
0.64
1
Storage, safety and handling

H-phraseH303, H313, H333
Hazard symbolXN
Intended useResearch Use Only (RUO)
R-phraseR20, R21, R22
Contact us

Telephone
Fax
Emailsales@aatbio.com
InternationalSee distributors
Bulk requestInquire
Custom sizeInquire
Technical SupportContact us
Request quotationRequest
Purchase orderSend to sales@aatbio.com
ShippingStandard overnight for United States, inquire for international
Page updated on April 1, 2026